# Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

Study · id `cardio:ct-nct05331144` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05331144](<https://clinicaltrials.gov/study/NCT05331144>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05331144

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 180 participants.

## Technical summary

Registry record NCT05331144. Randomized; single masking; primary purpose prevention. Start 2022-10-25 (actual); primary completion 2028-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT05331144, source copy `cardio:ctgov-nct05331144-2026-07-21`, retrieved 2026-10-26)
- Started: 2022-10-25 (actual) (ClinicalTrials.gov record NCT05331144, source copy `cardio:ctgov-nct05331144-2026-07-21`, retrieved 2026-10-26)
- Primary completion: 2028-06-01 (anticipated) (ClinicalTrials.gov record NCT05331144, source copy `cardio:ctgov-nct05331144-2026-07-21`, retrieved 2026-10-26)
- Completion: 2028-08-31 (anticipated) (ClinicalTrials.gov record NCT05331144, source copy `cardio:ctgov-nct05331144-2026-07-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05331144, source copy `cardio:ctgov-nct05331144-2026-07-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05331144-2026-07-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
- Acronym: IPAT
- Condition: Cognitively Normal Older Adults
- Condition: Hypertension
- Condition: Subjective Cognitive Decline
- Condition: Family History of Dementia
- Intervention (Drug): Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)
- Intervention (Other): PCP
- Lead sponsor: Rong Zhang
- Lead sponsor class: OTHER
- Collaborator: National Institute on Aging (NIA)
- Collaborator class: NIH
- Collaborator: Texas Health Resources
- Collaborator class: OTHER
- Collaborator: Michigan State University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as a collaborator: National Institute on Aging (`cardio:nia`)
- Registry lists this organization as a collaborator: Michigan State University (`cardio:org-michigan-state-university`)

## Provenance

Content hash: 91ebd4c5120ac94ff77612efbb3a228f0617356f572f7a840f8353fa7fb23b1d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
